Mounjaro is an injectable drug approved by the FDA to treat type 2 diabetes. Although approved for managing diabetes, studies indicate that Mounjaro’s active ingredient, tirzepatide, may be more effective than Wegovy or Ozempic for weight loss. This has led to a rise in patients using Mounjaro off-label for weight management. While the drug can aid in dramatic weight loss, high doses can also cause severe injuries like gastroparesis (stomach paralysis).
If you took Mounjaro and were later diagnosed with gastroparesis, call the Michael Brady Lynch Firm at 888-585-5970. You may be eligible for compensation for your injuries.
What’s the Mounjaro Lawsuit About?
Mounjaro is manufactured by Eli Lilly and was approved in 2022 to treat type 2 diabetes. Although the FDA hasn’t approved the drug for weight loss, one study by the New England Journal of Medicine found that patients prescribed Mounjaro lost more weight than patients who took semaglutide drugs like Wegovy and Ozempic. This led many physicians across the country to prescribe Mounjaro for weight management. With the increased number of patients using Mounjaro, the number of cases of adverse side effects due to taking Mounjaro also increased. Patients have reported severe gastrointestinal problems such as gastroparesis after taking high doses of Mounjaro. Mounjaro lawsuits claim Mounjaro’s manufacturer, Eli Lilly, failed to warn patients about the risks of gastroparesis while taking the drug.
Are There Long-Term Side Effects of Mounjaro?
While Moujaro is a relatively new drug and long-term studies haven’t been concluded, there have been reports of serious health issues like gallbladder disease, gallstones, and gastroparesis after taking at least two doses of Mounjaro. Other side effects include nausea, vomiting, pancreatitis, and hypoglycemia.
Eli Lilly Failed To Warn Patients
Mounjaro lawsuits claim that Eli Lilly knew about the risks of gastroparesis and other gastrointestinal issues but failed to warn patients and prescribers. The FDA issued a box warning on Mounjaro, the highest level of warning the FDA can issue, related to the risk of gallbladder disease while using the drug. However, Mounjaro’s label doesn’t include warnings about gastroparesis.
Eli Lilly responded with an open letter discouraging patients from using Moujaro for weight loss, indicating that the effects of Mounjaro haven’t been studied on patients with severe gastrointestinal issues and that the drug has only been approved for type 2 diabetes management.
Mounjaro Latest Cases
Mounjaro lawsuits have been consolidated into a multidistrict litigation with other GLP-1 receptor drugs like Wegovy and Ozempic. As of December 2024, there are 1,300 pending GLP-1 cases filed from patients who used Mounjaro, Wegovy, or Ozempic and were later diagnosed with gastroparesis. These cases claim that GLP-1 receptor drug manufacturers knew the risks of developing gastroparesis and failed to warn patients and prescribers.
Key Injuries and Mounjaro Lawsuit Eligibility
Our law firm is currently accepting GLP-1 drug cases from those who used Mounjaro, Wegovy, and Ozempic. The key injury criteria are:
- Gastroparesis
- Gallbladder disorders
- Ischemic Optic Neuropathy (eye stroke)
- Pancreatitis
- Diabetic Retinopathy
- Intestinal blockage or obstruction
You may be eligible for compensation if you used Mounjaro, Ozempic, or Wegovy and were later diagnosed with one of these conditions. Call our office at 888-585-5970 to discuss your case.
For information about the GLP-1 receptor MDL, view our resources: